Accueil > BIGG > Résultat de la recherche

    Résultats: 2

    Olaparib for previously treated BRCA mutation-positive hormone-relapsed metastatic prostate cancer

    England. National Institute for Health and Care Excellence.
    This evaluation uses new cost-effectiveness estimates to update olaparib for previously treated BRCA mutation-positive hormone-relapsed metastatic prostate cancer (NICE technology appraisal guidance TA831). No new clinical evidence was reviewed. Treatments for BRCA mutation-positive hormone-relapsed meta...
    Tumeurs de la prostate/traitement médicamenteux, Mutation/effets des médicaments et des substances chimiques, Protéine BRCA1, Antinéoplasiques hormonaux/usage thérapeutique
    Texte intégral

    Mobocertinib for treating EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer after platinum-based chemotherapy

    England. National Institute for Health and Care Excellence.
    Evidence-based recommendations on mobocertinib (EXKIVITY) for treating EGFR exon 20 insertion mutation-positive advanced non-small-cell lung cancer after platinum-based chemotherapy in adults. Commercial arrangement There is a simple discount patient access scheme for mobocertinib. NHS organisations ca...
    Inhibiteurs de protéines kinases/usage thérapeutique, Tumeurs du poumon/traitement médicamenteux, Platine/usage thérapeutique, Mutation/effets des médicaments et des substances chimiques, Facteur de croissance épidermique/antagonistes et inhibiteurs
    Texte intégral